- Regulus Therapeutics Enters into Agreement to be Acquired by Novartis . . .
SAN DIEGO, April 30, 2025 PRNewswire -- Regulus Therapeutics Inc (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into an agreement and plan of merger with Novartis AG ("Novartis") and an indirect
- Regulus Therapeutics
Our pipeline programs target kidney diseases of high unmet need, including ADPKD We are targeting the underlying biology of these diseases with a novel and potentially powerful approach: MicroRNA-based therapeutics News
- Novartis announces commencement of tender offer to acquire Regulus . . .
Basel, May 27, 2025 - Novartis today announced that Redwood Merger Sub Inc , a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0 001 per share (the “Shares”), of Regulus Therapeutics Inc , a Delaware corporation (“Regulus”), in exchange for (i
- Regulus: The Kingly Star | Space
Regulus is a bright star seen in the constellation Leo It's the brightest star in the constellation and among the brightest in Earth's night sky The star has two known companions nearby, a set
- Regulus Star – Facts Features About The Little King
Regulus, also known as Alpha Leonis, is the brightest star in the constellation Leo and the 21st brightest star in the night sky It has an apparent magnitude of 1 35 and is not actually a single star, but a multiple star system Regulus star is also known as Basiliskos, Cor Leonis (Lion’s Heart), Qalb al-Asad and Rex
- Novartis pays $800M to buy Regulus for phase 3-ready kidney drug
Novartis has committed another $1 7 billion to its ambition to become a kidney disease leader The Swiss drugmaker is making the outlay, around half of which is upfront, to buy Regulus
- Novartis grabs kidney drug developer Regulus in $1. 7bn deal
Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD) for $800 million upfront in a deal that could
- Novartis to acquire San Diego-based Regulus in deal worth up to $1. 7B
Swiss pharmaceutical giant Novartis is poised to expand its profile in the San Diego area, announcing plans to acquire Regulus Therapeutics, a local company on the cusp of bringing a potential
|